ENVB Stock Price, Enveric Biosciences, . Quote, Chart

Market Summary

USD0.84-0.06

Delayed

-6.67%

ENVB Stock Price

View Fullscreen

ENVB RSI Chart

ENVB Valuation

Market Cap

6.5M

Price/Earnings (Trailing)

-0.43

Price/Sales (Trailing)

0.17

EV/EBITDA

-0.32

Price/Free Cashflow

-0.56

ENVB Price/Sales (Trailing)

ENVB Profitability

Operating Margin

20.66%

EBT Margin

-37.74%

Return on Equity

-232.51%

Return on Assets

-170.3%

Free Cashflow Yield

-177.46%

ENVB Fundamentals

ENVB Revenue

Revenue (TTM)

35.4M

ENVB Earnings

Earnings (TTM)

-15.1M

Earnings Growth (Yr)

47.47%

Earnings Growth (Qtr)

28.49%

Breaking Down ENVB Revenue

Last 7 days

-5.6%

Last 30 days

-4.5%

Last 90 days

1.2%

Trailing 12 Months

-76.6%

How does ENVB drawdown profile look like?

ENVB Financial Health

Current Ratio

3.48

ENVB Investor Care

Shares Dilution (1Y)

273.00%

Diluted EPS (TTM)

-6.41

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2020	38.8M	36.1M	35.4M	0
2019	42.6M	42.6M	41.1M	39.9M
2018	47.3M	46.1M	44.2M	43.0M
2017	41.5M	47.1M	49.5M	48.6M
2016	23.0M	25.7M	31.3M	36.1M
2015	16.8M	16.8M	16.9M	20.4M
2014	6.1M	11.5M	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Enveric Biosciences, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 22, 2024	coveney kevin michael	acquired	-	-	60,000	chief financial officer
Feb 22, 2024	facchini peter j.	acquired	-	-	50,000	chief innovation officer
Feb 22, 2024	tucker joseph edward	acquired	-	-	100,000	chief executive officer
Sep 15, 2023	pasqualone frank	bought	2,140	2.14	1,000	-
Mar 13, 2023	coveney kevin michael	acquired	-	-	26,500	chief financial officer
Jan 25, 2023	facchini peter j.	acquired	-	-	17,000	chief innovation officer
Jan 25, 2023	tucker joseph edward	acquired	-	-	44,000	chief executive officer
Jan 25, 2023	hagel jillian marie	acquired	-	-	12,000	vice president of innovation
Jan 25, 2023	kanubaddi avani	acquired	-	-	10,000	president and coo
Oct 13, 2021	tucker joseph edward	acquired	-	-	16,374	chief executive officer

Which funds bought or sold ENVB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	unchanged	-	-	1.00	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	-30.00	100	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	sold off	-100	-354,900	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-3.13	-4,199	12,277	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	new	-	15,397	15,397	-%
May 15, 2024	CITADEL ADVISORS LLC	new	-	40,104	40,104	-%
May 14, 2024	AdvisorShares Investments LLC	added	68.39	54,450	238,833	0.04%
May 13, 2024	NATIONAL BANK OF CANADA /FI/	unchanged	-	-25.00	63.00	-%
May 13, 2024	UBS Group AG	added	49,730	4,970	4,983	-%
May 13, 2024	HRT FINANCIAL LP	new	-	63,000	63,000	-%

Are Funds Buying or Selling ENVB?

Are funds buying ENVB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ENVB

No. of Funds

Unveiling Enveric Biosciences, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.99%	273,109	SC 13G
Feb 06, 2024	intracoastal capital, llc	6.2%	145,000	SC 13G/A
Feb 05, 2024	hudson bay capital management lp	4.54%	110,357	SC 13G/A
Feb 14, 2023	advisorshares trust	5.60%	116,295	SC 13G
Feb 08, 2023	intracoastal capital, llc	9.4%	206,136	SC 13G/A
Feb 07, 2023	hudson bay capital management lp	5.04%	110,357	SC 13G
Feb 06, 2023	alpha capital anstalt	262%	47,028	SC 13G/A
Aug 01, 2022	intracoastal capital, llc	9.99%	129,842	SC 13G

Recent SEC filings of Enveric Biosciences, Inc.

View All Filings

Date Filed	Form Type	Document
May 17, 2024	8-K	Current Report
May 15, 2024	10-Q	Quarterly Report
May 15, 2024	8-K	Current Report
May 03, 2024	424B5	Prospectus Filed
May 03, 2024	8-K	Current Report
Apr 16, 2024	ARS	ARS
Apr 16, 2024	DEF 14A	DEF 14A
Mar 28, 2024	8-K	Current Report
Mar 26, 2024	8-K	Current Report
Mar 26, 2024	10-K	Annual Report

Peers (Alternatives to Enveric Biosciences, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Enveric Biosciences, Inc. News

Latest updates

Enveric Biosciences, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3
Revenue	2.8%	8.00	8.00	10.00	9.00	9.00	11.00	11.00	10.00	11.00	11.00	11.00	11.00	13.00	12.00	12.00	12.00	10.00	7.00	7.00	8.00	4.00
Cost Of Revenue	2.5%	7.00	6.00	8.00	7.00	7.00	9.00	9.00	8.00	8.00	9.00	9.00	9.00	10.00	10.00	9.00	12.00	8.00	5.00	2.00	4.00	3.00
Gross Profit	3.8%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	2.00	3.00	2.00	2.00	2.00	1.00	3.00	1.00
Operating Expenses	-36.2%	0.00	1.00	1.00	4.00	3.00	4.00	3.00	13.00	-3.75	3.00	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	-40.5%	0.00	1.00	1.00	-6.78	3.00	3.00	3.00	3.00	3.00	3.00	3.00	-	-	-	-	-	-	-	-	-	-
R&D Expenses	24.2%	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	48.4%	0.00	0.00	0.00	0.00	-0.25	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-
Income Taxes	-259.3%	-0.03	0.00	0.00	0.00	0.00	0.00	-0.03	6.00	0.00	-	-	-2.39	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	36.4%	-0.99	-1.56	-1.77	-2.13	0.00	-1.24	-1.89	-13.44	6.00	-1.26	-1.57	-3.42	-4.06	-3.26	-	-	-	-	-	-	-
Net Income	30.9%	-0.57	-0.82	-1.10	1.00	0.00	-1.26	-1.86	-19.77	6.00	-1.26	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	105.8%	9.00	4.00	7.00	10.00	16.00	20.00	31.00	29.00	32.00	27.00	70.00	24.00	26.00	4.00	28.00	28.00	28.00	29.00	30.00	27.00	31.00
Current Assets	129.8%	8.00	4.00	6.00	9.00	15.00	18.00	22.00	19.00	23.00	18.00	22.00	22.00	23.00	2.00	11.00	10.00	10.00	0.00	9.00	11.00	11.00
Cash Equivalents	-100.0%	-	2.00	4.00	7.00	13.00	18.00	21.00	18.00	22.00	17.00	21.00	21.00	23.00	2.00	3.00	2.00	1.00	0.00	2.00	2.00	2.00
Net PPE	-10.9%	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Goodwill	-	-	-	0.00	0.00	0.00	0.00	1.00	2.00	2.00	2.00	9.00	-	-	-	14.00	14.00	14.00	14.00	14.00	14.00	14.00
Liabilities	-	-	-	-	-	-	4.00	7.00	6.00	8.00	4.00	14.00	5.00	7.00	11.00	15.00	15.00	18.00	2.00	19.00	14.00	19.00
Current Liabilities	1.0%	2.00	2.00	4.00	5.00	4.00	4.00	3.00	2.00	2.00	3.00	2.00	1.00	1.00	1.00	14.00	13.00	17.00	2.00	14.00	14.00	15.00
Shareholder's Equity	231.3%	6.00	2.00	2.00	5.00	10.00	15.00	23.00	22.00	24.00	22.00	55.00	19.00	19.00	3.00	13.00	13.00	10.00	11.00	13.00	11.00	11.00
Retained Earnings	-2.5%	-98.96	-96.50	-93.06	-90.24	-83.89	-79.21	-70.53	-68.05	-65.26	-60.74	-18.63	-15.92	-15.01	-11.76	-45.16	-44.09	-42.41	-4.89	-37.81	-37.87	-36.44
Additional Paid-In Capital	5.1%	106	101	96.00	96.00	95.00	94.00	94.00	90.00	89.00	83.00	74.00	35.00	34.00	15.00	58.00	57.00	53.00	3.00	50.00	48.00	47.00
Accumulated Depreciation	9.6%	0.00	0.00	-	-	-	0.00	-	-	-	-	0.00	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	166.3%	7.00	3.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-
Float	-	-	-	-	7.00	-	-	-	11.00	-	-	-	51.00	-	-	-	7.00	-	-	-	16.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-48.4%	-2,598	-1,751	-2,740	-4,465	-5,137	-3,462	-4,550	-4,585	-4,548	-4,067	-2,206	-2,021	-3,162	-2,249	-393	-351	-893	826	-	-490	-984
Share Based Compensation	-3.6%	351	365	373	880	533	529	645	678	769	7,768	487	751	3,592	-	-	-	-	-	-	-	-
Cashflow From Investing	100.0%	-	-38*	20*	17.00	-5.17	-6.19	-18.57	-53.89	-505	-189	3,055	-	-675	2.00	-6.17	3.00	-43.37	-56.63	-	-115	-111
Cashflow From Financing	3678.1%	6,658	-186	-105	-1,052	-	-1*	7,824	958	9,398	7*	-9*	18.00	24,882	3,599	228	493	1,212	-1,371	-	484	1,448

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ENVB Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses
General and administrative	$ 1,933,753	$ 2,948,400
Research and development	458,155	1,825,792
Depreciation and amortization	85,409	86,486
Total operating expenses	2,477,317	4,860,678
Loss from operations	(2,477,317)	(4,860,678)
Other (expense) income
Change in fair value of warrant liabilities	10,039	50,657
Change in fair value of investment option liability	11,398	119,505
Change in fair value of derivative liability		13,000
Interest income (expense), net	696	(11)
Total other income	22,133	183,151
Net loss before income taxes	(2,455,184)	(4,677,527)
Income tax expense	(1,731)
Net loss	(2,456,915)	(4,677,527)
Less preferred dividends attributable to non-controlling interest		12,329
Less deemed dividends attributable to accretion of embedded derivative at redemption value		110,991
Net loss attributable to shareholders	(2,456,915)	(4,800,847)
Other comprehensive loss
Foreign currency translation	17,906	1,968
Comprehensive loss	$ (2,439,009)	$ (4,798,879)
Net loss per share - basic	$ (0.61)	$ (2.31)
Net loss per share - diluted	$ (0.61)	$ (2.31)
Weighted average shares outstanding, basic	4,001,456	2,078,271
Weighted average shares outstanding, diluted	4,001,456	2,078,271

ENVB Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheet - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash	$ 6,356,036	$ 2,287,977
Prepaid expenses and other current assets	1,872,786	1,293,554
Total current assets	8,228,822	3,581,531
Other assets:
Property and equipment, net	452,228	507,377
Intangible assets, net	168,744	210,932
Total other assets	620,972	718,309
Total assets	8,849,794	4,299,840
Current liabilities:
Accounts payable	1,852,833	1,218,783
Accrued liabilities	487,464	1,075,643
Investment option liability	12,210	23,608
Warrant liability	15,431	25,470
Total current liabilities	2,367,938	2,343,504
Commitments and contingencies (Note 8)
Mezzanine equity
Series C redeemable preferred stock, $0.01 par value, 100,000 shares authorized, and 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023
Total mezzanine equity
Shareholders’ equity
Preferred stock, $0.01 par value, 20,000,000 shares authorized; Series B preferred stock, $0.01 par value, 3,600,000 shares authorized, 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023
Common stock, $0.01 par value, 100,000,000 shares authorized, 7,294,005 and 2,739,315 shares issued and outstanding as of March 31, 2024 and December 31, 2023	72,939	27,392
Additional paid-in capital	105,917,193	100,815,851
Stock subscription receivable		(1,817,640)
Accumulated deficit	(98,956,433)	(96,499,518)
Accumulated other comprehensive loss	(551,843)	(569,749)
Total shareholders’ equity	6,481,856	1,956,336
Total liabilities, mezzanine equity, and shareholders’ equity	$ 8,849,794	$ 4,299,840

About Enveric Biosciences, Inc.

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead program is EB-373, an active metabolite of psilocybin, which is in Phase 1 clinical trials for the treatment of anxiety disorders; EVM-301 for treating mental health; and EV104 CBD + Celecoxib conjugate for treating osteoarthritis. The company also developing cannabinoid-infused topical product for the treatment of radiodermatitis; and cannabinoid and COX-2 inhibitor conjugation that is in pre-clinical stage for the treatment of OA/acute pain. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

CEO	Dr. Joseph Edward Tucker Ph.D.
WEBSITE	enveric.com
INDUSTRY	Biotechnology
EMPLOYEES	25

Enveric Biosciences, Inc. Frequently Asked Questions

What is the ticker symbol for Enveric Biosciences, Inc.? What does ENVB stand for in stocks?

ENVB is the stock ticker symbol of Enveric Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Enveric Biosciences, Inc. (ENVB)?

As of Fri May 17 2024, market cap of Enveric Biosciences, Inc. is 6.51 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ENVB stock?

You can check ENVB's fair value in chart for subscribers.

What is the fair value of ENVB stock?

You can check ENVB's fair value in chart for subscribers. The fair value of Enveric Biosciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Enveric Biosciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ENVB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Enveric Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether ENVB is over valued or under valued. Whether Enveric Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Enveric Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ENVB.

What is Enveric Biosciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ENVB's PE ratio (Price to Earnings) is -0.43 and Price to Sales (PS) ratio is 0.17. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ENVB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Enveric Biosciences, Inc.'s stock?

In the past 10 years, Enveric Biosciences, Inc. has provided -0.427 (multiply by 100 for percentage) rate of return.